Cellular studies reveal mechanistic differences between taccalonolide A and paclitaxel

Cell Cycle

Volumn 10, Issue 13, 2011, Pages 2162-2171

  Risinger, April L ^a   Mooberry, Susan L ^a,b  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Antimitotic agent; Drug persistence; Laulimalide; Microtubule; Microtubule stabilizer; Microtubule targeted agent; Paclitaxel; Taccalonolide; Tubulin

Indexed keywords

ANTINEOPLASTIC AGENT; CELL EXTRACT; CELL PROTEIN; CYTOSOLIC PROTEIN; LAULIMALIDE; NOCODAZOLE; PACLITAXEL; TACCALONOLIDE A; TUBULIN; UNCLASSIFIED DRUG;

ARTICLE; BRAIN; CELL CYCLE PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMICAL ANALYSIS; CONTROLLED STUDY; CYTOSOL; CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; INTERPHASE; MICROTUBULE; PROTEIN POLYMERIZATION; PROTEIN STABILITY;

EID: 79960017904     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.13.16238     Document Type: Article

References (23)

1. Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 2010; 9:790-803.
2. Fojo T, Menefee M. Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. Ann Oncol 2007; 18, Suppl. 5:v3-8.
3. Pusztai L. Markers predicting clinical benefit in breast cancer from microtubule-targeting agents. Ann Oncol 2007; 18, Suppl. 12:xii15-20.
4. Galsky MD, Dritselis A, Kirkpatrick P, Oh WK. Cabazitaxel. Nat Rev Drug Discov 2010; 9:677-8.
5. Morris PG, Fornier MN. Microtubule active agents: beyond the taxane frontier. Clin Cancer Res 2008; 14:7167-72.
6. Nogales E, Wolf SG, Khan IA, Luduena RF, Downing KH. Structure of tubulin at 6.5 A and location of the taxol-binding site. Nature 1995; 375:424-7.
7. Ojima I, Chakravarty S, Inoue T, Lin S, He L, Horwitz SB, et al. A common pharmacophore for cytotoxic natural products that stabilize microtubules. Proc Natl Acad Sci USA 1999; 96:4256-61. (Pubitemid 29190323)
8. Elie-Caille C, Severin F, Helenius J, Howard J, Muller DJ, Hyman AA. Straight GDP-tubulin protofilaments form in the presence of taxol. Curr Biol 2007; 17:1765-70. (Pubitemid 47577538)
9. Bennett MJ, Barakat K, Huzil JT, Tuszynski J, Schriemer DC. Discovery and characterization of the laulimalide-microtubule binding mode by mass shift perturbation mapping. Chem Biol 2010; 17:725-34.
10. Tinley TL, Randall-Hlubek DA, Leal RM, Jackson EM, Cessac JW, Quada JC Jr, et al. Taccalonolides E and A: Plant-derived steroids with microtubulestabilizing activity. Cancer Res 2003; 63:3211-20. (Pubitemid 36735874)
11. Buey RM, Barasoain I, Jackson E, Meyer A, Giannakakou P, Paterson I, et al. Microtubule interactions with chemically diverse stabilizing agents: thermodynamics of binding to the paclitaxel site predicts cytotoxicity. Chem Biol 2005; 12:1269-79. (Pubitemid 41779467)
12. Risinger AL, Jackson EM, Polin LA, Helms GL, LeBoeuf DA, Joe PA, et al. The taccalonolides: microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms. Cancer Res 2008; 68:8881-8.
13. Vallee RB. A taxol-dependent procedure for the isolation of microtubules and microtubule-associated proteins (MAPs). J Cell Biol 1982; 92:435-42. (Pubitemid 12157416)
14. Komlodi-Pasztor E, Sackett D, Wilkerson J, Fojo T. Mitosis is not a key target of microtubule agents in patient tumors. Nat Rev Clin Oncol 2011; 8:244-50.
15. Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, et al. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res 2009; 15:1612-22.
16. Smith NF, Figg WD, Sparreboom A. Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro 2006; 20:163-75. (Pubitemid 43087700)
17. Dahut WL, Lakhani NJ, Gulley JL, Arlen PM, Kohn EC, Kotz H, et al. Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol Ther 2006; 5:22-7. (Pubitemid 43234973)
18. Mita A, Lockhart A, Chen TL, Bochinski K, Curtright J, Cooper W, et al. A phase I pharmacokinetic (PK) trial of XAA296A (discodermolide) administered every 3 wks to adult patients with advance solid malignancies. J Clin Oncol 2004; 22:2025.
19. Towle MJ, Salvato KA, Budrow J, Wels BF, Kuznetsov G, Aalfs KK, et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 2001; 61:1013-21.
20. Towle MJ, Salvato KA, Wels BF, Aalfs KK, Zheng W, Seletsky BM, et al. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res 2011; 71:496-505.
21. Vallee RB, Collins CA. Purification of microtubules and microtubule-associated proteins from sea urchin eggs and cultured mammalian cells using taxol, and use of exogenous taxol-stabilized brain microtubules for purifying microtubule-associated proteins. Methods Enzymol 1986; 134:116-27.
22. Krishan A. Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol 1975; 66:188-93.
23. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82:1107-12. (Pubitemid 20213250)